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Background: Structural modifications of thiazolidinediones at 3rd and 5th position have exhibited significant
biological activities. In view of the facts, and based on in silico studies carried out on thiazolidine-2,4-diones as
HIV-1- RT inhibitors, a novel series of 2,4-thiazolidinedione analogs have been designed and synthesized.
Methods: Title compounds were prepared by the reported method. Conformations of the structures were
assigned on the basis of results of different spectral data. The assay of HIV-1 RT was done as reported by Silprasit et al.
Antimicrobial activity was determined by two fold serial dilution method. Docking study was performed for the highest
active compounds by using Glide 5.0.
Results: The newly synthesized compounds were evaluated for their HIV-1 RT inhibitory activity. Among the
synthesized compounds, compound 24 showed significant HIV-1 RT inhibitory activity with 73% of inhibition
with an IC50 value of 1.31 μM. Compound 10 showed highest activity against all the bacterial strains.
A molecular modeling study was carried out in order to investigate the possible interactions of the highest
active compounds 24, 10 and 4 with the non nucleoside inhibitory binding pocket(NNIBP) of RT, active site
of GlcN-6-P synthase and cytochrome P450 14-α-sterol demethylase from Candida albicans (Candida P450DM)
as the target receptors respectively using the Extra Precision (XP) mode of Glide software.
Conclusion: A series of novel substituted 2-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-(phenyl)propanamides (4–31)
have been synthesized and evaluated for their HIV-1 RT inhibitory activity, antibacterial and antifungal activities. Some
of the compounds have shown significant activity. Molecular docking studies showed very good interaction.
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The thiazolidinedione scaffold has been identified to play
an essential role in medicinal chemistry [1,2]. Compounds
containing the thiazolidinedione moiety have been found
to exhibit a wide range of biological activities viz., antihy-
perglycemic [3], anti-inflammatory [4], antimalarial [5],
antioxidant [6], antitumor [7], cytotoxic [8], antimicrobial
[9], antiproliferative [10], MurD ligase inhibitor [11],
monoamine oxidase B (MAO-B) inhibitor [12] neuropro-
tective [13], COX-2 inhibitor [14] and chemotherapeutic
activities [15]. Recently, a novel series of thiazolidin-4-ones* Correspondence: radhe118@gmail.com
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unless otherwise stated.have emerged as selective NNRTIs [16]. However not much
work has been reported on thiazolidine −2,4- diones as
HIV-1-RT inhibitors.
HIV is the causative organism for AIDS and is con-
tinuously evolving and rapidly spreading throughout the
world as a global infection. The HIV infection targets the
monocytes expressing surface CD4 receptors and pro-
duces profound defects in cell-mediated immunity [17].
Overtime infection leads to severe depletion of CD4
T-lymphocytes (T-cells) resulting in opportunistic infec-
tions like tuberculosis (TB), fungal, viral, protozoal and
neoplastic diseases and ultimately death [18].
Reverse transcription of the single-stranded (+) RNA
genome into double-stranded DNA is an essential step in
the HIV-1 replication life-cycle and requires the concertedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(RNase H) active sites of HIV-1 reverse transcriptase (RT).
Due to its essential role in HIV-1 replication, RT is a
major target for anti-HIV drug development and two
classes of inhibitors, (1) the nucleoside and nucleotide
RT inhibitors and (2) the nonnucleoside RT inhibitors
(NNRTIs) have been approved by the United States Food
and Drug Administration (FDA) for the treatment of
HIV-1 infection [19]. Though the NNRTIs are effective
and generally well-tolerated in the majority of patients,
treatment durability is limited by drug-related side effects
and rapid emergence of resistance among HIV isolates.
Thus, the therapeutic efficacy of NNRTIs is mainly re-
stricted due to development of viral resistance to NNRTIs
associated with mutations that include K103N, L100I and
Y188L, and with the development of second generation
NNRTIs, the search for a more suitable NNRTI, which
blocks the replication of all existing resistant viral strains
and retains potency for longer periods of time by modifying
the existing drug classes or by incorporating appropriate
substitutions in the newer chemical scaffolds, according to
the pharmacophoric requirements using multi-disciplinary
approaches is the call of the day.
With the advent of AIDS and as a result of promiscuous
use of drug therapy, antibacterial cytotoxins, steroids, or
due to underlying disease or medical manipulation the nor-
mal defenses conferred by the microbial flora breaks down
resulting in the prevalence of opportunistic bacterial and
fungal infections. Bacterial diseases such as tuberculosis, ty-
phus, plague, diphtheria, typhoid fever, cholera, dysentery
and pneumonia have taken a high toll on humanity [20].
Along with this prevalence of multi-drug resistant micro-
bial pathogens as an important and challenging therapeutic
problem and therefore a search for newer antibacterial
agents is the call of the day [21].
Opportunistic fungal infections have emerged as import-
ant causes of morbidity and mortality in immunocom-
promised patients and such infections include candidiasis,
aspergillosis and mucormycosis [22]. A dramatic increase
in invasive fungal infections over the past decade has been
observed [23]. To overcome these problems, the develop-
ment of new and safe antifungal agents with higher select-
ivity and lower toxicity is urgently required.
Glucosamine-6-phosphate synthase (GlcN-6-P synthase,
L-glutamine:D-fructose-6P amidotransferase), is a new
target for antibacterials [24] and antifungals [25]. GlcN-6-
P synthase catalyzes the first step in hexosamine metabolism,
converting fructose 6-phosphate into glucosamine 6-
phosphate (GlcN6P) in the presence of glutamine.
The reaction catalyzed by GlcN-6-P synthase is irrevers-
ible, and is therefore considered as a committed step.
The end product of the pathway, N-acetyl glucosamine,
is an essential building block of bacterial and fungal
cell walls.Recent modeling studies report that azoles may be acting
as antimicrobials by inhibition of GlcN-6-P synthase [24].
The fungal cell wall, a structure essential to fungi and
lacking in mammalian cells, is an obvious target for anti-
fungal agents. Its major macromolecular components are
chitin, ß-glucan, and mannoproteins [26]. In fungi, lanos-
terol 14-α-demethylase, a member of the cytochrome
P450 superfamily, is an essential requirement for fungal
viability. Azoles inhibit fungal cytochrome P-450 14-α-
demethylase (DM) which is responsible for the conversion
of lanosterol to ergosterol leading to the depletion of
ergosterol in the fungal cell membrane [27-29]. Thus
cytochrome P-450DM plays a key role in fungal sterol
biosynthetic pathways, and this has been an important
target for design of potent antifungals [30].
Structural modifications of thiazolidinediones at 3rd
and 5th position have exhibited significant biological ac-
tivities [31]. In view of the mentioned above facts, and
based on in silico studies carried out on thiazolidine 2,4-
diones as HIV-1- RT inhibitors [32], a novel series of
2,4-thiazolidinedione analogs have been designed based
on the pharmacophoric model of NNRTIs 18 with the
thiazolidinedione moiety attached to the propionamide
moiety (−CH2-CH2-CO-NH-) constituting the “body
(hydrophilic)” flanked by aryl rings (hydrophobic) linked
to the 3rd and 5th position of the thiazolidinedione ring
and to that of substituted aromatic amines as the “wings”
to enhance the hydrophobicity of the molecules (Figure 1).
Herein we wish to report the synthesis of newer
thiazolidine-2,4- diones, which have been evaluated for
anti-HIV, antibacterial and antifungal activities. Binding
mode analyses for the compounds with the highest
HIV-1- RT inhibitory activity, antibacterial and antifungal
activities have been carried out to understand the pharma-




All reagents were purchased from commercial suppliers
like Sigma Aldrich, Merck India Ltd., Himedia and Rankem
chemicals. All reagents were GR or AR grade and were
used without purification. The purity and homogeneity of
the compounds were assessed by the TLC performed on
Merck silica gel 60 F254 aluminium sheets using chloro-
form: methanol (9:1) as eluents. Iodine chamber and
Shimadzu (UV-254) spectrometer were used for visualization
of TLC spots. Ashless Whatmann No.1 filter paper was
used for vacuum filtration. Melting points were deter-
mined on an SRS Opti-melting point automatic apparatus
and were uncorrected. Elemental data of C, H and N were
within ±0.4% of the theortical value as determined by
Perkin Elmer Model 240 analyzer. IR spectra (KBr disc/or
pallets) were recorded on SHIAMADZU FT/IR 8400 and
Figure 1 Pharmacophoric model of 2,4-thiazolidinedione analogs.
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were respectively recorded at 400 and 100 MHz with
BRUKER Advance Digital Spectrophotometer. Chemical
shifts are expressed in δ-values (ppm) relative to TMS as
an internal standard, using DMSO-d6. Chemical shifts are
expressed in δ-values (ppm) relative to TMS as an internal
standard, using DMSO-d6 and Mass spectra were re-
corded with a AZILANT Q-TOF Micromass LC-MS by
using (ESI+).
Methods
General Procedure for the preparation of compounds (4–31)
Compounds 4–31 were synthesized as per the reported
procedure [33]. Substituted 5-benzylidene-2,4-thiazolidi-
nediones (2a-l) (0.01 mol) and the corresponding 3-
chloro-N-phenylpropanamides (3a-l) (0.01 mol) were
dissolved in 20 ml of acetonitrile. 0.02 mol of triethyla-
mine was added dropwise to this solution with stirring.
The reaction mixture was refluxed for 12 h, evaporated in
rotary evaporator, cooled and poured into crushed ice and
then basified with solid potassium carbonate. The result-
ing precipitate was filtered, washed with water (3 × 100 ml)
and further washed with n-hexane (3 × 20 ml). The solid
residue obtained was recrystallized from methanol to yield
the desired compounds.
Thiazolidine-2,4-dione (1)
IR (KBr) cm−1: 3132 (NH stretching), 1741, 1681, 1586
(C = O), 1H-NMR (DMSO-d6, 400 MHz): 12.50
(s; 1H; NH), 4.39 (2H, s, CH2).
5-(benzylidene) thiazolidine-2,4-dione (2)IR (KBr) cm−1: 3146 (NH stretching), 3039 (Ar-CH
stretching), 2789 (C-CH stretching), 1741, 1693 (C =O
stretching).
1H-NMR (DMSO-d6, 400 MHz): 9.94 (s; 1H; NH),
8.11 (s; 1H; C = CH), 8.09-6.91 (m, 5H, Ar-H).
2-chloro-N-phenylpropionamide (3)
IR (KBr) cm−1: 3138 (NH stretching), 1689 (C =O
stretching), 1303 (C-CN stretching), 1H-NMR (DMSO-d6,
400 MHz): 8.60 (s; 1H; NH), 8.12-7.24 (5H, m, Ar-H),
4.82 (q; 1H; CH- CH3),1.58 (s; 3H; CH-CH3).
3-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-
(3-hydroxyphenyl)propanamide (4)
IR (KBr) cm−1: 3353 (OH stretching), 3153 (NH
stretching), 1741,1676, 1648 (C =O stretching), 1329
(C-N aliphatic stretching), 1H-NMR (DMSO-d6,
400 MHz): 10.39 (s; 1H; 3′′OH), 9.83(s; 1H; NH), 7.80
(s;1H; C = CH), 7.51-6.85(m; 9H; Ar-H), 3.93 (t; 2H;
N-CH2-CH2-CO), 2.66 (t; 2H; N-CH2-CH2-CO),
13C
NMR(δ)DMSO-d6: 167.0, 166.0, 164.5 (C =O), 149.1
(C, Ar), 140.0 (C, Ar), 136.0 (=CH-), 135.1 (C, Ar),
130.0 (CH, Ar), 129.2 (2C, CH, Ar), 128.5 (2C, CH,
Ar), 128.1, 124.3 (CH, Ar), 121.5 (C-5 TZD), 119.8
(CH, Ar), 117.1 (CH, Ar), 41.5 (CH2-CH2), 31.2
(CH2-CH2), MS (ESI+) m/z 369.0 (M+).
3-(5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-phenylpropanamide (5)
IR (KBr) cm−1: 3363 (OH stretching), 3153 (NH
stretching), 3045, 2962 (Ar-CH stretching), 1676, 1648,
1640 (C = O stretching), 1H-NMR (DMSO-d6,
400 MHz): 10.02 (s; 1H; 3′OH), 9.84 (s; 1H; NH), 7.80
(s; 1H; C = CH), 7.51-6.85 (m; 9H; Ar-H), 3.93 (t; 2H;
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(ESI+) m/z 369.0 (M+).
3-(5-(2-fluorobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-phenylpropanamide (6)
IR (KBr) cm−1: 3313 (NH stretching), 3051, 2929
(Ar-CH stretching), 1753, 1687, 1661 (C =O
stretching), 1136 (C-F stretching), 1H-NMR (DMSO-d6,
400 MHz): 10.03 (s; 1H; NH), 7.88 (s; 1H; C = CH),
7.58-6.98 (m; 9H; Ar-H), 3.93 (t; 2H; N-CH2-CH2-CO),
2.66 (t; 2H; N-CH2-CH2-CO), MS (ESI+) m/z 371.0 (M+).
3-(5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(3-hydroxyphenyl)propanamide (7)
IR(KBr) cm−1: 3525, 3416 (OH stretching), 3232 (NH
stretching), 3053, 2947 (Ar-CH stretching),1722, 1664,
1652 (C = O stretching), 1H-NMR (DMSO-d6,
400 MHz): 10.00 (s;1H; NH), 9.79 (s; 1H; 3′OH), 9.78
(s; 1H; 3′′OH), 7.80 (s; 1H; C = CH), 7.51-6.85 (m; 8H;
Ar-H), 3.90 (t; 2H; N-CH2-CH2-CO), 2.63 (t; 2H;
N-CH2-CH2-CO), MS (ESI+) m/z 385.1 (M+).
3-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-
(2-chlorophenyl)propanamide (8)
IR (KBr) cm−1: 3306 (NH stretching), 1743, 1683, 1649
(C =O stretching), 821 (C-Cl stretching), 1H-NMR
(DMSO-d6, 400 MHz): 10.02 (s; 1H; NH), 8.01(s; 1H;
C = CH), 7.91 -7.32 (m; 9H; Ar-H), 3.93(t; 2H; N-CH2-




IR (KBr) cm−1: 3386 (NH stretching), 2935, 2852
(C-CH3 stretching), 1747, 1703, 1685 (C =O stretching),
1H-NMR (DMSO-d6, 400 MHz): 10.05 (s; 1H; NH), 8.06
(s; 1H; C = CH), 8.02-7.20 (m; 7H; Ar-H), 3.33 (t; 2H;
N-CH2-CH2-CO), 2.66 (t; 2H; N-CH2-CH2-CO), 2.30




IR (KBr) cm−1: 3389 (OH stretching), 3198 (NH
stretching), 2995, 2885 (C-CH3 stretching) 1668, 1646,
1640 (C = O stretching),1H-NMR (DMSO-d6,
400 MHz): 10.20 (s; 1H; OH), 10.11 (s; 1H; NH), 7.90
(s; 1H; C = CH), 7.61-7.29 (m; 7H; Ar-H), 3.93 (t; 2H;
N-CH2-CH2-CO), 2.70 (t; 2H; CH2), 2.45 (s; 3H; 2′
CH3), 2.24 (s; 3H; 5′CH3),
13C NMR(δ)DMSO-d6:
166.7, 166.4, 164.5 (C =O), 148.1 (C, Ar), 135.8, 134.7,
133.0 (C, Ar), 132.8 (=CH-), 130.2, 129.0, 127.2,
125.4 (CH, Ar), 122.2 (CH, Ar), 121.5 (C-5 TZD), 120.2,
119.2 (CH, Ar), 116.0 (CH, Ar), 121.0, 119.4 (C-CH3), 41.5
(CH2-CH2), 31.2 (CH2-CH2), MS (ESI+) m/z 397.2 (M+).
3-(5-(2,4-dimethylbenzylidene)-2,4-dioxothiazolidin-3-
yl)-N-(2-hydroxyphenyl)propanamide (11)
IR (KBr) cm−1: 3404 (OH stretching), 3136 (NH
stretching), 2742 (C-CH3 stretching), 1734, 1681, 1641(C = O stretching), 665 (C-S stretching), 1H-NMR
(DMSO-d6, 400 MHz): 10.15 (s; 1H; 2′OH), 10.03
(s; 1H; NH), 8.06 (s; 1H; C = CH), 8.03 -7.20 (m; 7H;
Ar-H), 3.92 (t; 2H; N-CH2-CH2-CO), 2.66 (s; tH; CH2),




IR (KBr) cm−1: 3304 (OH stretching), 3203 (NH
stretching), 2980 (C-CH3 stretching), 1658, 1650, 1642
(C =O stretching), 690 (C-S stretching), 1H-NMR
(DMSO-d6, 400 MHz): 10.20 (s; 1H; 2′′OH), 10.11 (s; 1H;
NH), 7.90 (s; 1H; C =CH), 7.61-7.27 (m; 7H; Ar-H), 3.90
(t; 2H; N-CH2-CH2-CO), 2.63 (s; tH; CH2), 2.24-2.27
(s; 6H; 2′5′CH3), MS (ESI+) m/z 397.0 (M+).
3-(5-(2,4-dihydroxybenzylidene)-2,4-dioxothiazolidin-
3-yl)-N-(2-hydroxyphenyl)propanamide (13)
IR (KBr) cm−1: 3657, 3566, 3412 (OH stretching), 3390
(NH stretching), 3087, 3032 (Ar-CH stretching), 1687,
1669, 1656 (C = O stretching), 1H-NMR (DMSO-d6,
400 MHz): 12.44 (s; 1H; 2′′OH), 10.70 (s; 1H; 2′OH),
10.01 (s; 1H; 4′OH), 9.98 (s; 1H; NH), 8.01 (s; 1H; C=CH),
8.03-7.24 (m; 7H; Ar-H), 3.98 (t; 2H; N-CH2-CH2-CO),
2.23 (t; 2H; 2 CH2), MS (ESI+) m/z 401.2 (M+).
3-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-(2-
chloro-4-methylphenyl)propanamide (14)
IR (KBr) cm−1: 3281 (NH stretching), 1664, 1650
(C =O stretching), 1329 (C-N aromatic stretching),
783 (C-Cl stretching), 1H-NMR (DMSO-d6, 400 MHz):
10.17 (s; 1H; NH), 7.93 (s; 1H; C = CH), 7.64 -6.44
(m; 8H; Ar-H), 2.66-3.96 (t; 2H; N-CH2-CH2-CO), 2.31
(t; 2H; N-CH2-CH2-CO), 2.26 (s; 3H; 4′′CH3), MS
(ESI+) m/z 401.5 (M+).
3-(5-benzylidene-2,4-dioxothiazolidin-3-yl)-N-(4-
chloro-3-methylphenyl)propanamide (15)
IR (KBr) cm−1: 3283 (NH stretching), 1684, 1654, 1609
(C =O stretching), 1305 (C-N aromatic stretching), 761
(C-Cl stretching), 1H-NMR (DMSO-d6, 400 MHz):
10.19 (s; 1H; NH), 7.93 (s; 1H; C = CH), 7.93-6.23
(m; 8H; Ar-H), 2.67-3.95 (t; 2H; N-CH2-CH2-CO),
2.30 (s; 3H; 4′′CH3), 2.27 (t; 2H; N-CH2-CH2-CO), MS
(ESI+) m/z 401.3 (M+).
3-(5-(2-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-p-tolylpropanamide (16)
IR (KBr) cm−1: 3215 (NH stretching) 1666, 1655, 1645
(C =O stretching), 717 (C-Cl stretching),1H-NMR
(DMSO-d6, 400 MHz): 10.02 (s; 1H; NH), 7.88 (s; 1H;
C = CH), 7.58 -7.23 (m; 8H; Ar-H), 3.94 (t; 2H; N-CH2-
CH2-CO), 2.67 (t; 2H; N-CH2-CH2-CO), 2.30 (s; 3H;
4′′CH3), MS (ESI+) m/z 401.3 (M+).
3-(5-(2,3,4-trihydroxybenzylidene)2,4-dioxothiazolidin-
3-yl)-N-p-tolylpropanamide (17)
IR(KBr)cm−1: 3649, 3629, 3595 (OH-stretching), 3312
(NH-stretching), 2869 (C-CH3 stretching), 1745,
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400 MHz): 14.09 (s; 1H; 2′OH), 10.09 (s; 1H; 3′OH),
9.50 (s; 1H; 4′OH), 9.31 (s;1H; NH), 8.06(s;1H; C = CH),
8.04 -7.20 (m; 6H; Ar-H), 3.84 (t; 2H; N-CH2-CH2-CO),
2.39 (s; 3H; 4′′CH3), 2.33 (t; 2H; N-CH2-CH2-CO), MS
(ESI+) m/z 415.3 (M+).
3-(5-(3-hydroxybenzylidene)-2,4-dioxothiazolidin-3-
yl)-N-(2-chloro-5-methylphenyl)- propanamide (18)
IR (KBr) cm−1: 3308 (OH stretching), 3223 (NH
stretching), 3057, 2960 (Ar-CH stretching), 2924, 2854
(C-CH3 stretching), 1691,1656, 1646 (C =O stretching),
752 (C-Cl stretching), 1H-NMR (DMSO-d6, 400 MHz):
10.19 (s; 1H; 3′OH), 10.11 (s; 1H; NH), 7.93 (s; 1H;
C = CH), 7.64-6.23 (m; 7H; Ar-H), 3.96-2.66 (t; 2H;
N-CH2-CH2-CO), 2.30 (s; 3H; 5′′CH3), 2.27 (t; 2H;
N-CH2-CH2-CO), MS (ESI+) m/z 417.2 (M+).
3-(5-(2-fluorobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(2-chloro-4-methylphenyl)- propanamide (19)
IR (KBr) cm−1: 3306 (NH stretching), 2926, 2856
(C-CH3 stretching), 1743, 1693, 1654 (C =O stretching),
1282 (C-F stretching), 754 (C-Cl stretching), 1H-NMR
(DMSO-d6, 400 MHz): 10.02 (s; 1H; NH), 7.88 (s; 1H;
C = CH), 7.58-7.23 (m; 7H; Ar-H), 3.99 ((t; 2H; N-CH2-
CH2-CO), 2.60 (t; 2H; N-CH2-CH2-CO), 2.28 (s; 3H;
4′′CH3), MS (ESI+) m/z 419.2 (M+).
3-(5-(3,5-dimethylbenzylidene)-2,4-dioxothiazolidin-3-
yl)-N-(2-chloro-4-methylphenyl)- propanamide (20)
IR (KBr) cm−1: 3267 (NH stretching), 3039 (Ar-CH
stretching), 2916, 2858 (C-CH3 stretching), 1681,
1651,1644 (C = O stretching), 742 (C-Cl stretching)
1H-NMR (DMSO-d6, 400 MHz): 10.07 (s; 1H; NH),
8.04 (s; 1H; C = CH), 7.84-7.20 (m; 6H; Ar-H), 3.92
(t; 2H; N-CH2-CH2-CO), 2.66 (t; 2H; N-CH2-CH2-
CO), 2.30 (s; 6H; CH3), 2.24 (s; 3H; 4’CH3).
3-(5-(2-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(4-nitrophenyl)propanamide (21)
IR (KBr) cm−1: 3145 (NH stretching), 1685, 1657, 1644
(C =O stretching), 1311 (C-NO2 stretching), 776 (C-Cl
stretching),1H-NMR (DMSO-d6, 400 MHz): 10.39 (s;
1H; NH), 8.01(s;1H; =CH), 7.91-7.32 (m; 8H; Ar-H),
3.91 (t; 2H; N-CH2-CH2-CO), 2.72 (t; 2H; N-CH2-
CH2-CO), MS (ESI+) m/z 432.8 (M+).
3-(5-(2-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(2-nitrophenyl)propanamide (22)
IR (KBr) cm−1: 3306 (NH stretching), 1743, 1693, 1612
(C =O stretching), 1342 (C-NO2 stretching), 754 (C-Cl
stretching), 1H-NMR (DMSO-d6, 400 MHz): 10.00
(s; 1H; NH), 7.80 (s; 1H;C = CH), 7.51-6.85 (m; 8H;




IR (KBr) cm−1: 3267 (NH stretching), 1702, 1664, 1650
(C =O stretching), 1373 (C-NO2 stretching), 752 (C-Clstretching), 1H-NMR (DMSO-d6, 400 MHz): 10.00
(s; 1H; NH), 7.80 (s; 1H; C = CH), 7.51 -6.87 (m; 8H;





IR (KBr) cm−1: 3649, 3629, 3587(OH stretching), 3312
(NH stretching) 2975, 2931 (Ar-CH stretching), 2896
(C-CH3 stretching), 2546 (SH-stretching), 1688, 1647,
1638 (C = O stretching), 1H-NMR (DMSO-d6,
400 MHz): 13.96 (s; 1H; 2′OH), 10.09 (s; 1H; 3′OH),
9.50 (s; 1H; 4′OH), 9.31 (s;1H; NH), 8.01 (s;1H; C = CH),
7.90-7.18 (m; 6H; Ar-H), 3.84 (t; 2H; N-CH2-CH2-CO),
3.49 (s; 1H; 2′′SH), 2.30 (t; 2H; N-CH2-CH2-CO),
13CNMR(δ)DMSO-d6: 167.2, 165.5, 164.5 (C =O), 148.2,
145.2, 142.1, 136.0 (C, Ar), 136.1 (=CH-), 130.2, 129.0,
125.8 (CH, Ar), 124.3 (C, Ar), 123.6, 123.0 (CH, Ar),
121.5 (C-5 TZD), 110.1, (C, Ar), 109.3 (CH, Ar), 41.5
(CH2-CH2), 31.2 (CH2-CH2), MS (ESI+) m/z 432.8 (M+).
3-(5-(2,4-dihydroxybenzylidene)-2,4-dioxothiazolidin-
3-yl)-N-(3-chloro-2-methylphenyl)propanamide (25)
IR (KBr) cm−1: 3630, 3444 (OH stretching), 3273 (NH
stretching), 3053(Ar-CH stretching), 2793 (C-CH3
stretching), 1730, 1674, 1648 (C =O stretching), 792
(C-Cl stretching), 1H-NMR (DMSO-d6, 400 MHz):
10.51 (s; 1H; 2′OH), 10.19 (s; 1H; 4′OH), 9.69 (s; 1H; NH),
8.09 (s; 1H; C =CH), 7.41-7.16 (m; 6H; Ar-H), 3.95 (t; 2H;
N-CH2-CH2-CO), 2.68 (t; 2H; N-CH2-CH2-CO), 2.19
(s; 3H; 2′′CH3), MS (ESI+) m/z 432.9 (M+).
3-(5-(4-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(2-chloro-4-methylphenyl)propanamide (26)
IR (KBr) cm−1: 3198 (NH stretching), 2918, 2848 (C-
CH3 stretching), 1750, 1672, 1658 (C = O stretching),
1307 (C-N aromatic stretching), 748 (C-Cl stretching),
1H-NMR (DMSO-d6, 400 MHz): 9.65 (s; 1H; NH), 7.94
(s; 1H; C = CH), 7.90 -6.53 (m; 7H; Ar-H), 3.94-3.91
(t; 2H; N-CH2-CH2-CO), 2.70-2.76 (t; 2H; N-CH2-
CH2-CO), 2.32 (s; 3H; CH3),
13C NMR(δ)DMSO-d6:
167.6, 165.8, 164.5 (C =O), 135.7 (=CH-), 135.6, 133.0,
131.9, 132.0, 131.0 (C, Ar), 130.0 (3C, CH, Ar) 127.8,
(3C, CH, Ar), 124.2 (CH, Ar), 121.5 (C-5 TZD), 113.1,
(C, Ar), 112.2, 109.5, 103.7 (CH, Ar), 41.5 (CH2-CH2),
31.2 (CH2-CH2), 20.7 (CH3), MS (ESI+) m/z 436.2 (M+).
3-(5-(4-chlorobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(2-chloro-5-methylphenyl)propanamide (27)
IR (KBr) cm−1: 3273 (NH stretching), 1739, 1670, 1652
(C =O stretching), 808 (C-Cl stretching), 1H-NMR
(DMSO-d6, 400 MHz): 9.64 (s; 1H; NH), 7.95 (s; 1H;
C = CH), 7.62 -6.20 (m; 7H; Ar-H), 3.94-3.20 (t; 2H;
N-CH2-CH2-CO), 2.76-2.32 (t; 2H; N-CH2-CH2-CO),
2.23 (s; 3H; 5′′CH3), MS (ESI+) m/z 435.9 (M+).
3-(5-(2-bromobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(2-hydroxyphenyl)propanamide (28)
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stretching), 1688, 1669, 1646 (C =O stretching), 668
(C-Br stretching), 1H-NMR (DMSO-d6, 400 MHz):
9.97 (s; 1H; 2′′OH), 9.84 (s; 1H; NH), 7.80 (s; 1H;
C = CH), 7.51-6.85 (m; 8H; Ar-H), 3.91 (t; 2H; N-CH2-
CH2-CO), 2.64 (t; 2H; N-CH2-CH2-CO),
13CNMR(δ)
DMSO-d6: 167.2, 165.2, 164.5 (C =O), 148.9, 138.1,
135.3 (=CH-), 135.1 (C, Ar), 132.3, 130.1, 128.1, 127.1,
127.0 (CH, Ar), 121.5 (C-5 TZD), 113.0, (C, Ar), 112.9,
109.5, 104.8 (CH, Ar), 41.5 (CH2-CH2), 31.2 (CH2-CH2),
MS (ESI+) m/z 448.0.
3-(5-(2-bromobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(3-hydroxyphenyl)propanamide (29)
IR (KBr) cm−1: 3444 (OH stretching), 3315 (NH
stretching), 1752, 1680, 1650 (C =O stretching), 680
(C-Br stretching), 1H-NMR (DMSO-d6, 400 MHz):
9.84 (s; 1H; OH), 9.61 (s; 1H; NH), 7.81 (s; 1H; C =CH),
7.52-6.86 (m; 8H; Ar-H), 3.91 (t; 2H; N-CH2-CH2-CO),
2.64 (t; 2H; N-CH2-CH2-CO), MS (ESI+) m/z 448.2 (M+).
3-(5-(2-bromobenzylidene)-2,4-dioxothiazolidin-3-yl)-
N-(4-nitrophenyl)propanamide (30)
IR (KBr) cm−1: 3207 (NH stretching), 1710, 1685, 1658
(C =O stretching), 1319 (C-NO2 stretching), 750 (C-Br
stretching), 1H-NMR (DMSO-d6, 400 MHz): 9.73
(s; 1H; NH), 8.12 (s; 1H; C = CH), 8.09 -7.53 (m; 8H;




IR (KBr) cm−1: 3284 (NH stretching), 3014, 2922
(C-CH3 stretching) 1702, 1676, 1652 (C =O stretching),
779 (C-Br Stretching), 675 (C-Br stretching), 1H-NMR
(DMSO-d6, 400 MHz): 10.11 (s; 1H; NH), 7.90 (s; 1H;
C = CH), 7.61 -7.29 (m; 7H; Ar-H), 3.90 (t; 2H; N-CH2-
CH2-CO), 2.64 (t; 2H; N-CH2-CH2-CO), 2.45 (s; 3H; 3′′
CH3), MS (ESI+) m/z 480.2 (M+).
Biological assays
The standard strains were procured from Institute of
Microbial Technology, Chandigarh and National Chemical
Laboratory, Pune. Antimicrobial activity was determined
by two fold serial dilution method [34] in duplicates
against pathogenic microorganisms Gram-positive bac-
teria: Staphylococcus aureus (NCIM 2122), Bacillus subti-
lis (MTCC 121), Gram-negative bacteria: Escherichia coli
(MTCC118), Pseudomonas aeruginosa (MTCC 647),
Salmonella typhi (NCIM 2501), Klebsiella pneumonia
(MTCC 3384) and fungus Candida albicans (MTCC 227),
Aspergillus niger (NCIM 1056). Test compounds were dis-
solved in 10% DMSO, to produce a 2000 μg/ml stock so-
lution. These test tubes were serially diluted to give a
concentration of 100, 50, 25, 12.5, 6.25, 3.125, 1.56, and
0.78 μg/mL. MHB (Mueller-Hinton Broth) was used for
bacteria and SDB (Sabouraud Dextrose Broth) was usedfor fungus. The cell density of each inoculum was adjusted
in sterile water of a 0.5 McFarland standard. A final con-
centration of ~107 CFU/mL and ~106 CFU/mL was ob-
tained for bacteria and fungus, respectively. Microbial
inocula were added to the twofold diluted samples. The
test tubes were incubated 18–24 h at 37° C ±1°C for bac-
teria and 2–5 days at 25°C ±1°C for fungus. Ciprofloxacin
and fluconazole were used as standard drugs. The highest
dilution of the test compound that completely inhibited
the growth of test organism was considered as the MIC
value of the test compound and was expressed in μg/ml.
HIV-1 reverse transcriptase inhibition assay
The assay of HIV-1 RT was done as reported by Silprasit
et al. [35]. All reagents used were provided in the EnzChek®
Reverse Transcriptase Assay Kit (Molecular Probes, USA).
A mixture of 5 μL of 1 mg/mL 350 bases-poly(rA) ribonu-
cleotide template and 5 μL of 50 μg/mL oligo d(T)16 primer
in a nuclease-free microcentrifuge tube were incubated at
room temperature (25°C) for 1 hour to allow the primer/
template annealing. The primer/template was prepared
by 200-fold dilution in polymerization buffer. The primer/
template was aliquoted and kept at −20°C until used. Five
microliter of 8 μM stock purified HIV-1 reverse tran-
scriptase was aliquoted and kept at −80°C until used. The
working enzyme was diluted to 400 nM with 50 mM
Tris–HCl, 20% glycerol, 2 mM DTT, pH 7.5.
The assays were performed in a total volume 15 μL of
the polymerization reaction. The reaction containing
3 μl of 400 nM recombinant HIV-1 RT (the final concen-
tration is 80 nM), 2 μL of TE buffer (10 mM Tris–HCl at
pH 7.5) were added and gently mixed on ice prior. The
polymerization reaction was initiated by the addition of
10 μL of the primer/template and incubated at room
temperature for 30 minutes. After the reactions reached
the desired incubation time, 5 μL of 0.2 M EDTA was
added to stop the polymerization reaction (RTControl).
The blank reaction was prepared by mixing 5 μL of
0.2 M EDTA with enzyme before adding primer/template
(RTBlank). After termination of the reactions, the plate
was gently shaken and incubated at room temperature for
3 min to allow the formation of a stable heteroduplex
DNA/RNA complex, followed by addition of 180 μL of
PicoGreen reagent diluted 700-fold with TE buffer for
each well, making the final volume 200 μL and incuba-
tion at room temperature in the dark for 3 min, dur-
ing which PicoGreen binds to double-stranded DNA and
RNA-DNA hybrids, was followed by measurement of
fluorescence with a fluorometer (excitation 485 nm; emis-
sion 535 nm).
To test the inhibition efficiency of the compounds, all the
compounds were dissolved in dimethyl sulfoxide (DMSO)
to make a 20 mM stock solution. Ten micromolar working
solution of each inhibitor was further diluted by 10 mM
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of each inhibitor and 3 μL of 400 nM recombinant HIV-1
RT were added and gently mixed on ice prior. The re-
action was initiated by the addition of 10 μL of the primer/
template and incubated at room temperature for
30 minutes. After the reactions reached the desired incu-
bation time, 5 μL of 0.2 M EDTA was added to stop the
polymerization reaction. The relative inhibitory effect of
HIV-1 RT activity was compared by using percent inhib-
ition, which was calculated via the following eq (1):
% relative inhibition ¼






   100
ð1Þ
Determination of the IC50 inhibition value
Determination of the IC50 was done by adding 2 μL of
each two-fold serial dilution of inhibitors. Two microli-
ters of each test compound was diluted serially 2-fold.
Then, 2 μL of 30 ng/μL purified HIV-1 RT was added
and mixed. A volume of 4 μL of the template/primer
polymerization buffer was added into each well. The
mixtures were incubated at 37°C for 10 min. The reac-
tions were stopped with 5 μL of 200 mM EDTA and im-
mediately incubated on ice for 30 min. The activity was
determined by the PicoGreen–fluorometric method. The
reaction was repeated three times and were determined
using Graph pad Prism4 version with a non-linear re-
gression model.
Computational method with Glide 5.0
Docking study was performed for the highest active
compounds by using Glide 5.0 (Schrodinger) [36] installed
in a single machine running on a 3.4 GHz Pentium 4 pro-
cessor with 1GB RAM and 160 GB Hard Disk with Red
Hat Linux Enterprise version 5.0 as the operating system.
Protein structure preparation
The X-ray crystallographic structure of (PDB code 1RT2,
2VF5 and 1EA1) was obtained from Brookhaven Protein
Data Bank (RCSB) [37]. All water molecules were re-
moved from the complex, and the protein was minimized
using the protein preparation wizard. Partial atomic
charges were assigned according to the OPLS_AA force
field. A radius of 10 Å was selected for active site cavity
during receptor grid generation for 2VF5. After assigning
charge and protonation state finally refinement (energy
minimization) was done using MM3 force field runs.
Crystallographic structure of the complex between cyto-
chrome P450 14-R-sterol demethylase fromMycobacterium
tuberculosis (Mycobacterium P450DM) and fluconazolewas present in the Protein Data Bank with the ID 1EA1
[38]. The high homology existing between these two analo-
gous enzymes [39] suggested building a simple model con-
sisting of the crystallographic structure of the complex
1EA1 in which the residues that are arranged in a range
of 7 Å from fluconazole, were substituted with those of
Candida P450DM according to reported method [33].
Only 12 substitutions were made by replacement of the
residues Pro77, Phe78, Met79, Arg96, Met99, Leu100,
Phe255, Ala256, His258, Ile322, Ile323 and Leu324 by
Lys77, His78, Leu79, Leu96, Lys99, Phe100, Met255,
Gly256, Gln258, His322, Ser323 and Ile324, which were
thought to be necessary for the ligand-receptor inter-
action. The complex between the chimeric enzyme thus
obtained and was then minimized.
Ligand structure preparation
All the compounds used in the docking study with Glide
were built within maestro by using build module of
Schrodinger Suite 2008. These structures were geometry
optimized by using the Optimized Potentials for Liquid
Simulations-2005 (OPLS_2005) force field with the steepest
descent protocol followed by truncated Newton conjugate
gradient protocol. Partial atomic charges were computed
using the OPLS_2005 force field.
Docking protocol and their validation
All docking calculations were then performed using the
“Extra Precision” (XP) mode of Glide Program 5.0. A
grid was prepared with the center defined by the co-
crystallized ligand. During the docking process, initially
Glide performed a complete systematic search of the
conformational, orientational and positional space of the
docked ligand and eliminated unwanted conformations
using scoring followed by energy optimization. Finally
the conformations were further refined via Monte Carlo
sampling of pose conformation. Predicting the binding
affinity and rank-ordering ligands in database screens
was implemented by modified and expanded version of
the Glide scoring function. The most suitable method of
evaluating the accuracy of a docking procedure is to de-
termine how closely the lowest energy pose predicted by
the scoring function resembles an experimental binding
mode as determined by X-ray crystallography. Docking
validation was performed with an obtained RMSD value
of 0.370 Å for 1RT2, 1.674 Å for 2VF5 and 2.094 Å for




An attempt has been made to incorporate aryl groups in
the 3rd and 5th position of the thiazolidinedione structure











































Scheme 1 Reagents and conditions: (i) Water, Conc. HCl, reflux 10-12 h (ii) ethanol, piperidine, reflu 4 h (iii) Glacial acetic acid (GAA),
0-5°C, 0.5 h, 4rt, stirring (iv) CH3CN, triethylamine, reflux 12h. General scheme for the synthesis of compounds (4–31).
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of thiourea and chloroacetic acid, and then hydrolysed
with 2 N HCl to afford 2,4-thiazolidinedione (1). Knoeve-
nagel condensation of 2,4-thiazolidinedione and appro-
priate aryl aldehydes was carried out in ethanol under
reflux conditions containing catalytic amount of piperi-
dine, as base, to form the corresponding substituted
5-benzylidene-2,4-thiazolidinediones (2) [33]. N-chloro-3-
(phenylamino)propanamides (3) were prepared by the
reported method [40]. Substituted N-chloro-3-(phenylamino)
propanamides (3) were thus prepared by reacting appro-
priate aryl amines with 3-chloropropionyl chloride in the
presence of glacial acetic acid in cold condition. The
substituted 5-benzylidene-2,4-thiazolidinediones (2) were
condensed with substituted N-chloro-3-(phenylamino)
propanamides (3) in the presence of triethylamine
using acetonitrile as the solvent to get substituted 3-(5-
benzylidene-2,4-dioxothiazolidin-3-yl)-N-phenylpropanamides
4–31.
The physical data are given in Table 1. FTIR, 1H-NMR
and mass spectral data for all the synthesized compoundsare given in the above experimental protocols. The IR
spectrum of all the final compounds exhibited very similar
features and showed the expected bands for the characteris-
tic groups present in the compounds such as N-H stretch-
ing in the range of 3390–3136 cm−1 and C =O stretching
in the range of 1750–1645 cm−1 to confirm the presence of
thiazolidinedione ring system. 1H NMR showed a charac-
teristic singlet peak assigned to a δ value in the range
of 10.39-9.31 thus confirming the presence of NH pro-
ton of thiazolidinedione scaffold in compounds 4–31.
The methylenic (C = CH) protons of compounds 4–31
were seen as a singlet between 8.12-7.80 δppm while
aromatic protons appeared as multiple peaks within
the range 8.04-6.20 δ ppm. Characteristic triplet of 2
protons was assigned at δ ranging 3.99-2.66 to the
methylenic protons of N-CH2-CH2-CO. Similarly; a
triplet of 2 protons was assigned to the methylenic
protons of N-CH2-CH2-CO observed at δ ranging
2.76-2.20 for all the compounds 4–31. The 13C NMR
depicted the peaks of thiazolidine-2,4-dione (TZD)
nucleus within the range δ 166.2-164.3 (thiazolidine-
Table 1 Physical data of synthesized compounds (4–31)
Comp. no. R R' Mol. formula Yield (%) M.P. (°C) M.W. Elemental analysis calculated/found
C H N
4 H 3-OH C19H16N2O4S 57 289 368.41 61.94 4.38 7.60
61.90 4.34 7.55
5 3-OH H C19H16N2O4S 55 243 368.41 61.94 4.38 7.60
61.90 4.36 7.66
6 2-F H C19H14ClFN2O3S 52 186 370.40 56.37 3.49 6.92
56.33 3.44 6.88
6 2-F H C19H14ClFN2O3S 52 186 370.40 56.37 3.49 6.92
56.33 3.44 6.88
7 3-OH 3-OH C19H16N2O5S 58 129 348.41 59.37 4.20 7.29
59.32 4.16 7.24
8 H Cl C19H15ClN2O3S 55 183 386.85 58.99 3.91 7.24
58.55 3.89 7.26
9 2,4-CH3 4-CH3 C22H22N2O3S 62 284 394.49 66.98 5.62 7.10
66.95 5.56 7.05
10 2,5-CH3 2-OH C21H20N2O4S 64 302 396.46 63.62 5.08 7.07
63.58 5.11 7.10
11 2,4-CH3 2-OH C21H20N2O4S 58 189 396.46 63.62 5.08 7.07
63.58 5.11 7.11
12 3,5-CH3 2-OH C21H20N2O4S 56 293 396.46 63.62 5.08 7.07
63.59 5.06 7.02
13 2,4-OH 2-OH C19H16N2O6S 52 243 400.41 56.99 4.03 7.00
56.95 4.00 7.03
14 H 2-Cl, 4-CH3 C20H17ClN2O3S 58 109 400.88 59.92 4.27 6.99
59.88 4.24 6.95
15 H 4-Cl, 3-CH3 C20H17ClN2O3S 56 113 400.88 59.92 4.27 6.99
59.88 4.24 6.95
16 2-Cl 4-CH3 C20H17ClN2O3S 68 279 400.88 59.92 4.27 6.99
59.95 4.24 6.96
17 2,3,4-OH 4-CH3 C20H18N2O6S 44 253 414.43 57.96 4.38 6.76
59.95 4.42 6.72
18 3-OH 2-Cl,5-CH3 C20H17ClN2O4S 66 173 416.88 57.62 4.11 6.72
57.59 4.08 6.70
19 2-F 2-Cl,4-CH3 C20H16ClFN2O3S 60 175 418.87 57.35 3.85 6.69
57.30 3.81 6.66
20 3,5-CH3 2-Cl,4-CH3 C22H21ClN2O3S 55 308 428.93 61.60 4.93 6.53
61.56 4.88 6.49
21 2-Cl 4-NO2 C19H14ClN3O5S 58 282 431.85 52.84 3.27 9.73
52.86 3.21 9.69
22 2-Cl 2-NO2 C19H14ClN3O5S 66 174 431.85 52.84 3.27 9.73
52.86 3.21 9.69
23 4-Cl 2-NO2 C19H14ClN3O5S 52 240 431.85 52.84 3.27 9.73
52.86 3.22 9.70
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Table 1 Physical data of synthesized compounds (4–31) (Continued)
24 2,3,4-OH 2-SH C19H16N2O6S2 53 119 432.47 52.77 3.73 6.48
52.74 3.68 6.44
25 2,4-OH 3-Cl,2-CH3 C20H17ClN2O5S 50 78 432.88 55.49 3.96 6.47
55.45 3.94 6.42
26 4-Cl 4-Cl,3-CH3 C20H16Cl2N2O3S 70 302 435.32 46.62 3.13 5.44
46.58 3.08 5.40
27 4-Cl 2-Cl,5-CH3 C20H16Cl2N2O3S 65 158 435.32 46.62 3.13 5.44
46.58 3.08 5.40
28 2-Br 2-OH C19H15BrN2O4S 52 113 447.30 51.02 3.38 6.26
51.10 3.40 6.30
29 2-Br 3-OH C19H15BrN2O4S 58 237 447.30 51.02 3.38 6.26
51.10 3.40 6.30
30 2-Br 2-NO2 C19H14BrN3O5S 62 297 476.66 47.91 2.96 8.82
47.88 2.94 8.85
31 3-Br 4-Cl,3-CH3 C20H16BrCl2N2O3S 67 309 479.77 50.07 3.36 5.84
50.11 3.31 5.80
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for thiazolidine-2,4-dione-C-5 atom at δ 121.5.
Biological activity
All the synthesized compounds were also evaluated for
in vitro antibacterial activity against Gram-positive bac-
teria: Staphylococcus aureus (NCIM 2122), Bacillus sub-
tilis (MTCC 121), Gram-negative bacteria: Escherichia
coli (MTCC118), Pseudomonas aeruginosa (MTCC 647),
Salmonella typhi (NCIM 2501), Klebsiella pneumonia
(MTCC 3384) and fungus Candida albicans (MTCC
227), Aspergillus niger (NCIM 1056), by using the two-
fold serial dilution technique and the results are summa-
rized in Table 2. Ciprofloxacin was used as the standard
for antibacterial activity and fluconazole was used as the
standard for antifungal activity.
Compound 10 showed highest activity against all the
bacterial strains. Compound 4 and 10 showed highest
activity against E. coli while compound 24 exhibited
moderate activity against the same bacterial strain while
exhibited weak activity against all the other bacterial
strains. Compound 5 and 7 exhibited highest activity
against B. subtilis and K. pneumoniae respectively while
compound 17 exhibited moderate activity against all the
three bacterial strains B. subtilis, E. coli and S. typhi.
Compound 8 exhibited moderate activity against S. aur-
eus. However, all these compounds exhibited activity less
than that of standard drug ciprofloxacin. Rest of the
compounds showed mild to moderate activity against all
other bacterial strains.
Compound 4 exhibited excellent activity against the
fungal strains C. albicans and A. niger. In fact, the activitywas higher than that of standard fluconazole. Compound
7, 8, 15, 19, 21, 24 and 27 also exhibited very high activity
against both the fungal strains comparable to the standard
drug. Compounds 5, 10, 11, 18 and 28 exhibited signifi-
cant activity against C. albicans while showing moderate
activity against A. niger. All other compounds showed
moderate to weak antifungal activity against both the fun-
gal strains.
The introduction of phenyl groups substituted at dif-
ferent positions with electronegative groups such as
chloro, hydroxyl and nitro enhances the antimicrobial
activity, particularly evident in case of antifungal activity.
However, the introduction of one methyl group does not
have much influence in the increase or decrease of anti-
fungal activity as in case of compounds 19 and 27. The
introduction of two methyl groups in the phenyl ring
directly substituted at the 5th position of the thiazolidine −
2,4-dione nucleus results in slight decrease in the antifun-
gal activity but increases antibacterial activity as is evident
from the activity of compound 10.
The newly synthesized compounds were evaluated for
their HIV-1 RT inhibitory activity. Percentage of inhibition
has given in Table 3. Among the synthesized compounds,
compound 24 showed significant HIV-1 RT inhibitory
activity with 73% of inhibition with an IC50 value of
1.31 μM. Compound 23 also showed 58% inhibition,
however its IC50 value was negligent. Rest of compounds
showed weak activity.
From the results of HIV-1-RT inhibitory activity, it is evi-
dent that compound 24 with hydroxyl groups substituted
at 2, 3 and 4 positions of the phenyl ring attached at the
5th position of the thiazolidinedione ring with a linker
Table 2 In vitro antibacterial and antifungal activity data
of test compounds: 4-31
Minimum inhibitory concentration MIC (μg/mL)
Comp. code S a B.s E.c P.a S.t K.P C.a A.n
4 50 25 6.25 50 50 50 3.12 6.25
5 50 6.25 25 25 50 50 12.5 25
6 100 50 50 100 100 50 25 50
7 25 50 50 50 25 6.25 6.25 12.5
8 12.5 25 25 50 25 50 12.5 6.25
9 100 100 100 100 50 100 50 50
10 3.12 6.25 6.25 6.25 6.25 6.25 12.5 25
11 25 50 100 100 25 100 12.5 25
12 50 25 25 50 50 25 25 50
13 25 25 50 25 50 50 50 25
14 50 50 25 50 50 100 25 25
15 25 50 12.5 50 50 100 12.5 25
16 100 50 100 100 100 100 >100 >100
17 50 12.5 12.5 50 12.5 25 50 50
18 50 100 50 100 100 100 12.5 25
19 25 50 25 100 50 25 12.5 12.5
20 >100 >100 >100 >100 >100 >100 >100 >100
21 50 25 50 50 50 25 6.25 12.5
22 50 50 50 50 50 50 25 25
23 50 50 50 50 50 50 50 25
24 100 100 6.25 100 100 12.5 12.5 12.5
25 100 100 50 100 50 50 50 50
26 50 50 25 50 50 50 25 25
27 25 25 12.5 50 25 50 6.25 12.5
28 50 50 50 100 50 100 12.5 25
29 25 25 25 100 25 100 25 12.5
30 50 100 50 100 100 >100 25 12.5
31 >100 >100 >100 >100 >100 >100 >100 >100
*CIP. 0.78 0.78 0.78 0.78 0.78 0.78 - -
*FLU. - - - - - - 12.5 12.5
S.a: Staphylococcus aureus, B.s:Bacillus subtilis, E.c:Escherichia coli, P.a:
Pseudomonas aeruginosa, S.t: Salmonella typhi, K.p: Klebsiella pneumonia,
C.a: Candida albicans, A.n: Aspergillus niger.
*CIP: Ciprofloxacin, *FLU: Fluconazole.
Experiments in duplicates.
Table 3 HIV-RT inhibitory activity






























*IC50 (μM) of compound 24 is1.31 & efavirenz* 0.0717, concentration used was
1 μM, experiments in duplicates.
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second phenyl ring substituted with a 2-mercapto group
positively influenced the activity.
According to the above obtained data, we found that
compounds 4–31 exhibited promising antimicrobial activ-
ities. In case of HIV-1-RT inhibitory activity, only com-
pound 24 was found to be significantly active while the
others exhibited weak non-nucleoside reverse transcript-
ase activity.Binding mode analysis
With the aim of rationalizing the biological data ob-
tained and considering the best obtained in vitro results
for the compounds 4–31, a molecular modeling study
was carried out in order to investigate the possible inter-
actions of the highest active compounds 24, 10 and 4
with the non nucleoside inhibitory binding pocket
(NNIBP) of RT, active site of GlcN-6-P synthase and
cytochrome P450 14-α-sterol demethylase from Candida
albicans (Candida P450DM) as the target receptors re-
spectively using the Extra Precision (XP) mode of Glide
software [36].
To validate the Glide software, firstly the interaction
between TNK651 and HIV-1 RT was modeled. Superim-
position of the experimental bound (co-crystallized)
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Glide are shown in Figure 2a. Glide successfully repro-
duced the experimental binding conformations of TNK
651 in the NNRTI-binding pocket of HIV-1 RT with an
acceptable root-mean-square deviation (RMSD) of 2.4 Å.
Visual inspection was then performed on the resulting
docking solutions of the compound 24 to analyze the
binding mode and key protein ligand interactions and was
compared with that of the experimentally determined
binding mode and interactions of the bound ligand TNK-
651 and the standard efavirenz. The key interactions were
mainly hydrogen bonding interactions with Lys103 and
Lys101 respectively. The carbonyl oxygen at position 4 in
the thiazolidinedione moiety forms a strong H-bond inter-
action with the NH terminal group of Lys103.Another
strong H-bond interaction of the hydroxyl group at
the ortho position of the first phenyl ring with one of car-
bonyl oxygen atoms of Lys101 was observed. The phenyl
ring in the 2, 3, 4-trihydroxybenzaldehyde moiety along
with the thiazolidinedione moiety was oriented in the
bigger hydrophobic pocket formed by Phe227, Pro225
Leu234 Tyr181, Tyr188, Leu100 and Val179 while the
CH2CH2CONH linker showed favorable interaction
with the amino acid residues Tyr318, Pro236 and
Val106. Docking score of the compound 24 (Glide XP
score-11.30) was lower than the bound ligand TNK-651
(Glide XP score-13.29) but comparable to that of stand-
ard efavirenz (Glide XP score-11.33) .Possible interac-
tions for the reference ligand TNK-651, efavirenz and
compound 24 have been shown in Figure 2a,b and c
respectively.
The active site of GlcN-6-P synthase (PDB code 2VF5)
consists of 16 amino acid residues as Glu488, Ser303,
Ala602 Ser347, Ser349, Gln348, Thr302, Thr352, Val605,
Ala400, Cys300, Val399, Leu601, Leu484, Ser401 and
Lys603 as shown in Figure 2d. Figure 2d and f shows the
docked poses of the reference ligand and of highest active
compound 10 respectively. The binding mode of GlcN-6-
P synthase (2VF5) with its bound inhibitor glucosamine-
6-Phosphate (Figure 2d) shows 9 hydrogen bonds with
residues Glu488, Ser303, Ala602, Ser347, Ser349, Gln384,
Thr302, Thr352, hydrophobic interactions with Val605,
Ala400, Cys300, Val399, Leu601, Leu484 and electrostatic
interactions with Ser401 and Lys603 with a docking score −
7.16. Docking validation was performed with an RMSD
value of 1.674 Å ensuring precision and reproducibility of
the docking process. The docked pose of active compound
10 (Glide XP score −4.89) has been depicted in Figure 2f.
It was interesting to note that three important hydro-
gen bonds are formed by compound 10. The hydroxyl
group on the benzylidene moiety forms a hydrogen bond
with the carbonyl oxygen of Thr302. The NH in the
CH2CH2CONH linker forms a strong hydrogen bond
with the carbonyl oxygen of Val399. Another strongH-bond is evident between the carbonyl oxygen of
thiazolidinedione with the NH terminal group of Ala602.
The 2-hydroxyphenyl group makes favorable interaction
with the side chain of Ala 400. The thiazolidinedione ring
shows favorably oriented towards the residues Leu601,
Cys300, Val605 and Ala353. The linker (CH2CH2CONH)
shows favorable interactions with Leu484.
As the target enzyme Candida P450DM is a membrane-
bound enzyme, it is difficult to crystallize by X-ray analysis;
therefore, no experimental data has been available for
the structure of this enzyme. However, the crystallo-
graphic structure of the complex between cytochrome
P450 14-α-sterol demethylase from Mycobacterium tu-
berculosis (Mycobacterium P450DM) and fluconazole is
present in the Protein Data Bank with the ID 1EA1. A
perusal of the literature showed that high homology exists
between the two analogous enzymes, Candida P450DM
and Mycobacterium P450DM [42].
A chimeric enzyme of Candida P450DM complexed
with fluconazole was modeled following the procedure
of Rosello et al. [42]. Fluconazole maintained practically the
same orientation as in 1EA1 with a docking score of −6.01.
In fluconazole, interaction of triazole ring with heme is co-
ordination of N atom with Fe atom of heme, while another
triazole ring also forms π– π stacking interactions with
Tyr78 and His78. The diflurophenyl group also forms π–π
stacking interactions with Phe100. Phenyl ring shows
hydrophobic interactions with amino acid residues Leu79,
Leu96, Phe83, Met255, Ala256, Leu321 and Val 434.
Docking validation was performed with RMSD value of
2.094 Å ensuring precision and reproducibility of the
docking process (Figure 2e).
To illustrate the binding mode of the newly synthe-
sized compounds in the active site of chimeric 1EA1, the
docked pose of the highest active compound 4 (Glide
XP score −8.13) has been analysed as follows (Figure 2g).
The key interactions are mainly hydrogen bonding in-
teractions. The hydroxyl group on the benzylidene
moiety forms a hydrogen bond with Hie392. The CO
in the CH2CH2CONH linker forms a strong coordin-
ate bond with Hem460. The aromatic ring forms π–π
stacking interactions with Phe83 residue. The thiazoli-
dinedione ring is oriented in the hydrophobic pocket
formed by Tyr181, Phe100, Met255, Val395 and Leu79.
Both phenyl rings attached to the thiazolidinedione
nucleus makes favorable interactions with the side chains
of Leu96, Al173, Tyr76, Cys394, Phe387, Ile324, Ala389
and Leu321.
These docking results demonstrate that hydrogen bond
interactions, hydrophobic interactions and the coordinate
bond with the Hem residue in 1EA1 are very important
for binding of compound 4 with the active site residues
and may be responsible for the very high antifungal activ-
ity as shown by compound 4.
Figure 2 2D sketch views. Binding mode of a) Ref. ligand (TNK-651) b) efavirenz c) compound 24 into the NNIBP of 1RT2 d) Glucosamine-6-Phosphate
(2VF5) e) Ref ligand fluconazole (chimeric 1EA1) and compounds f) 10 in the active site of 2VF5 g) 4 in the active site of chimeric 1EA1.
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In the present study, a series of thiazolidinedione analogs
have been synthesized and their structures have been
characterized by IR, NMR and mass spectroscopy. All the
newly synthesized compounds were tested for HIV-1- RT
inhibitory activity by microplate assay method and for
antimicrobial activity by two fold serial dilution method.
From the modeling studies as well as from the SAR, elec-
tronegative groups substituted at various positions of the
phenyl rings with a thiazolidinedione scaffold may be re-
sponsible for the very high HIV-1-RT inhibitory activity of
compound 24. In case of antibacterial activity the methyl
groups substituted in the phenyl group attached to the 5th
position of the thiazolidinedione ring system plays a sig-
nificant role while in case of antifungal activity the electro-
negative groups, particularly hydroxyl groups substituted
in the various positions of both the phenyl groups are re-
sponsible for enhanced antifungal activity. The study en-
courages us to consider a new molecular skeleton of
thiazolidinediones substituted at the 3rd and 5th position
by aryl groups with adequate spacers may be identified as
a potential lead compound for the development of ant-
HIV agents with the ability to combat opportunistic bac-
terial and fungal infections.
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